The industrial technology firm projects $12M-$15M in CapEx for fiscal 2026 as it advances its Dothan facility transition. Allient Inc. outlined a $12M-$15M capital expenditure plan for fiscal 2026, aiming to complete its Dothan facility transition by the end of Q3. The com
Phibro Animal Health raises full-year guidance after Q3 net sales rose 10% to $383 million and adjusted EBITDA climbed 11% to $60 million. Phibro Animal Health Corporation updated its fiscal 2026 guidance, projecting net sales between $1.46 billion and $1.5 billion. Adjust
The company reported Q1 2026 production growth of 6% year-over-year, exceeding its 2026 guidance midpoint. Magnolia Oil & Gas announced plans to achieve approximately 5% production growth in 2026, supported by $155M in bolt-on acquisitions. The company’s Q1 2026 output ros
Arrowhead Pharmaceuticals targets Q3 topline data for SHASTA-3/4 and a supplemental NDA submission by year-end 2026. Arrowhead Pharmaceuticals announced plans to release topline data for its SHASTA-3/4 programs in Q3 2026. The company also aims to file a supplemental new d
The biotech firm raises its outlook after Q1 2026 progress in partner milestones boosts revenue visibility. OmniAb Inc. (OABI) expects 2026 revenue between $28M and $33M, driven by advancements in partner programs. The updated forecast reflects stronger pipeline visibility
The eyewear retailer reported Q1 2026 revenue of $242 million, up 8.3% year-over-year, with adjusted EBITDA at $30 million. Warby Parker projected 2026 revenue between $959 million and $976 million, aligning with its strategic push into AI-powered glasses later this year.
Fox Factory reported Q1 2026 revenue of $368.7 million and adjusted EBITDA of $35.7 million, exceeding guidance ranges. Fox Factory Holding Corp. (FOXF) delivered Q1 2026 revenue of $368.7 million, aligning with the high end of its guidance range, while adjusted EBITDA rea
CTMX shares rise after management confirms liquidity through at least H2 2028 and targets H1 2027 for Varseta-M registrational study. CytomX Therapeutics (CTMX) announced its cash runway now extends to at least the second half of 2028, providing financial flexibility for o
Kontoor Brands outlines earnings guidance and capital return plans following its Q1 2026 management review. Kontoor Brands (KTB) has targeted adjusted earnings per share from continuing operations of $5.15 to $5.25 for Q1 2026. The company also announced plans to divest it
Blend Labs forecasts incremental top-line growth next year after exceeding Q1 2026 revenue and non-GAAP operating income estimates. Blend Labs set a 10%-15% incremental revenue growth target for 2027, driven by transitioning its Autopilot feature to paid tiers starting lat
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.